Palisades Investment Partners Acquires $5.26M Stake in Travere Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 50m ago
0mins
Source: Fool
- New Investment Position: Palisades Investment Partners initiated a new position in Travere Therapeutics by acquiring 137,768 shares valued at $5.26 million in Q4 2025, indicating a bullish outlook on the company's growth potential.
- Strong Stock Performance: As of January 19, 2026, Travere Therapeutics shares were priced at $27.87, reflecting a 50.89% increase over the past year, outperforming the S&P 500 by 34.01 percentage points, showcasing market recognition of its potential value.
- Significant Revenue Growth: The sales of Travere's FILSPARI drug surged 155% year-over-year to $90.9 million in Q3 2023, contributing to a total revenue increase from $62.9 million to $164.9 million, demonstrating strong market demand for its products.
- FDA Review Catalyst: With the FDA reviewing Travere's FILSPARI for potential approval in specific disease treatments, Palisades' investment reflects optimism about Travere's future market performance, especially with anticipated growth following potential FDA approval.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 42.89 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 29.730
Low
31.00
Averages
42.89
High
49.00
Current: 29.730
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
